Agnieszka Marta Sobczak

Agnieszka Marta Sobczak

Auto-generated profile, based on publicly available information

Agnieszka Marta Sobczak

University Hospital in Poznań, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2026 in Journal of Pre-Clinical and Clinical Research
Verified
Journal Article
Open access
BGBartosz Gołembiewski
Bartosz Gołembiewski
GMGrzegorz Mulski
Grzegorz Mulski
MMMartyna Manicka
Martyna Manicka
MBMichał Baranowicz
Michał Baranowicz
WMWeronika Mazurkiewicz
Weronika Mazurkiewicz
ŁŁŁukasz Łapaj
Łukasz Łapaj

30 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAlicja Szymczak
Alicja Szymczak
AJAnna Jaworowicz
Anna Jaworowicz
JPJoanna Piasecka
Joanna Piasecka
BGBartosz Gołembiewski
Bartosz Gołembiewski
GMGrzegorz Mulski
Grzegorz Mulski
ASAgnieszka Marta Sobczak
Agnieszka Marta Sobczak
Background: Hematological malignancies remain a substantial contributor to global cancer morbidity and mortality, and as such – a major public health issue. Recent evidence has revealed that Solanaceae alkaloids (SAs) could contribute to developing new treatment strategies in hematological oncology. Objective: To critically evaluate contemporary evidence on the anti-cancer effects of SAs, including alpha-solanine, solanidine, solasodine, solamargine, tomatine and tomatidine as well as their potential applicability as bioactive compounds in hematology-related research and therapy. Methods: This narrative review was informed by studies retrieved from widely recognized search engines and databases, including PubMed/MedLine, Google Scholar, ScienceDirect, Wiley, Scopus and Springer Link. The search was conducted using the following MeSH terms: “Solanaceae Alkaloids”, “Solanine”, “Solanidine”, “Solasodine”, “Solamargine”, “Tomatine”, “Tomatidine”, “Leukemia”, “Lymphoma”, “Hematology” and "Blood cancer". Original English-language studies published between 2005 and 2025 were included. Case reports and non-primary data sources were excluded. No meta-analysis was performed. Results: Steroidal alkaloids from Solanaceae species demonstrate significant cytotoxic and anti-proliferative effects against various leukemia and lymphoma cell lines. These compounds have the capacity to inhibit tumor growth and survival through multiple mechanisms, including the induction of apoptosis, oncosis, and cell cycle arrest. Conclusions: Solanaceae-derived steroidal alkaloids exhibit promising antitumor activity in hematological malignancies by modulating apoptosis, survival signaling pathways, and mechanisms of drug resistance. Their ability to enhance chemosensitivity supports further investigation as potential therapeutic or adjuvant agents, pending validation in in vivo and clinical studies.

27 August 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
ZBZuzanna Borecka
Zuzanna Borecka
ASAgnieszka Marta Sobczak
Agnieszka Marta Sobczak
ASAlicja Szymczak
Alicja Szymczak
AJAnna Jaworowicz
Anna Jaworowicz
JPJoanna Piasecka
Joanna Piasecka
WMWeronika Mazurkiewicz
Weronika Mazurkiewicz
Background Statins are among the most widely prescribed lipid lowering agents and substantially reduce cardiovascular morbidity and mortality. However, accumulating evidence suggests that statin therapy may be associated with disturbances in glucose homeostasis and an increased risk of statin associated dysglycemia and new onset diabetes (SANOD). Alterations in the gut microbiota have emerged as a potential contributor to these metabolic effects. Aim This narrative review summarizes current evidence on the relationship between statin therapy, gut microbiota alterations, and statin associated dysglycemia and new onset diabetes, with emphasis on the underlying biological mechanisms and their potential clinical relevance. Materials and methods A literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science, with Google Scholar used as a supplementary source. Publications available up to July 20, 2026, were considered. Clinical, observational, experimental, and relevant review studies evaluating associations between statin therapy, gut microbiota, glucose homeostasis, and new onset diabetes were qualitatively synthesized. A total of 46 publications were included. Results Current evidence suggests that statins may alter gut microbiota composition and metabolic activity. Proposed mechanisms include modulation of bile acid metabolism, short chain fatty acid production, incretin signaling, intestinal barrier integrity, and inflammatory pathways. These microbiota mediated alterations may contribute to individual susceptibility to statin associated dysglycemia and new onset diabetes. However, the available evidence remains heterogeneous and is largely based on observational and experimental studies. Conclusions The gut microbiota represents a biologically plausible mediator of statin associated metabolic effects, but current evidence is insufficient to establish causality or support microbiota guided clinical decision making. Further well designed prospective and mechanistic studies are needed to clarify these interactions and their clinical significance.

11 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MBMichał Baranowicz
Michał Baranowicz
WMWeronika Mazurkiewicz
Weronika Mazurkiewicz
ZBZuzanna Borecka
Zuzanna Borecka
ASAgnieszka Marta Sobczak
Agnieszka Marta Sobczak
ASAlicja Szczot
Alicja Szczot
MMMartyna Manicka
Martyna Manicka
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by a rapidly progressive clinical course, ultimately leading to complete paralysis and a profound deterioration of physical and cognitive well-being. For decades, riluzole remained the sole approved therapeutic option. The pharmacological landscape has recently experienced significant revolution. While a definitive cure remains elusive, recent advancements have introduced novel, targeted agents into clinical practice, marking a critical milestone in ALS management. This review presents recent findings and emerging trends in ALS pharmacotherapy. Furthermore, it examines the complex pathophysiology of this multidimensional disease, highlighting the intrinsic biological challenges that complicate the development of universally effective, disease-modifying treatments.

29 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
JPJoanna Piasecka
Joanna Piasecka
BGBartosz Gołembiewski
Bartosz Gołembiewski
GMGrzegorz Mulski
Grzegorz Mulski
MMMartyna Manicka
Martyna Manicka
MBMichał Baranowicz
Michał Baranowicz
AJAnna Jaworowicz
Anna Jaworowicz
Acne vulgaris is one of the most common dermatological conditions worldwide, estimated to affect up to 85–90% of the population at some point in their lives. While most frequently observed in adolescents and young adults, an increasing number of patients over the age of 25- long after the period of puberty- are presenting with this problem. The pathogenesis of acne is complex, involving sebaceous gland hyperactivity, follicular hyperkeratosis, excessive proliferation of Cutibacterium acnes, and inflammation, all of which lead to a disruption of skin homeostasis. The causes of this deregulation are primarily attributed to hormonal imbalances, particularly the influence of androgens, as well as carbohydrate metabolism dysfunction and chronic stress. For decades, several groups of medications have been used interchangeably, including isotretinoin, hormonal contraceptives, antibiotics, spironolactone, and various topical agents. Although these treatments have proven effective in many cases, a significant proportion of patients still face side effects, lack of clinical improvement, or disease recurrence. After many years without the introduction of any innovative medication, a new option has emerged for patients struggling with acne vulgaris: clascoterone. Its mechanism of action consists of blocking androgen receptors in the skin, which suppresses sebaceous gland hyperactivity and reduces inflammation. As a topical preparation, it carries a much lower risk of systemic side effects than oral treatments. In this article, we aim to present this new drug in comparison to currently available therapeutic options, looking forward to a potential breakthrough in the treatment of this common dermatosis.

7 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
ASAgnieszka Sobczak
Agnieszka Sobczak
ASAlicja Szczot
Alicja Szczot
AJAnna Jaworowicz
Anna Jaworowicz
JPJoanna Piasecka
Joanna Piasecka
BGBartosz Gołembiewski
Bartosz Gołembiewski
ZBZuzanna Borecka
Zuzanna Borecka
Background: Cutaneous warts caused by human papillomavirus (HPV) are among the most prevalent dermatological conditions, with up to one third of non-genital lesions becoming recalcitrant to conventional destructive therapies. The limited efficacy of treatment and high recurrence rates associated with first-line modalities have driven growing interest in immunotherapeutic approaches. Methods: This narrative review was conducted following a structured literature search of PubMed database, covering publications from January 2016 to March 2026, with the aim of synthesizing current evidence on intralesional immunotherapy and HPV vaccination in the management of recalcitrant extragenital cutaneous warts. Results: Among intralesional agents, the MMR vaccine demonstrates the most consistent efficacy, with pooled complete response rates of 63.2% and distant wart clearance in 62.0% of patients. Intralesional HPV vaccination achieved the highest complete response rate in a placebo-controlled trial (75%), with a favorable safety. The evidence for intralesional vitamin D3 is heterogeneous; the sole double-blind, placebo-controlled trial showed no significant benefit over placebo. Therapeutic intramuscular HPV vaccination achieved complete resolution in 61.2% of patients across available studies, while routine prophylactic vaccination status did not influence wart resolution in standard treatment settings. Conclusions: Intralesional MMR and HPV vaccines represent the most promising therapeutic modalities for recalcitrant cutaneous warts. Standardization of treatment protocols and large multicentre randomized controlled trials are required to establish definitive evidence-based recommendations.